A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma
A. C. Roy, S. R. Park, D. Cunningham, Y. K. Kang, Y. Chao, L. T. Chen, C. Rees, H. Y. Lim, J. Tabernero, F. J. Ramos, M. Kujundzic, M. B. Cardic, C. G. Yeh, A. de Gramont
Navegar pels temes de recerca de 'A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma'. Junts formen un fingerprint únic.